Mutagenic Evaluation of Fluoxetine and Fluoxetine-Galactomannan Complex Through the Analysis of Chromosomal Aberrations in Human Peripheral Leukocytes and Salmonella typhimurium/Microssome Assay

• Autor(a) principal: Cavalcanti, Bruno Coêlho
• Data de Publicação: 2022
• Outros Autores: da Silva, Cecília Rocha, Neto, João Batista de Andrade, Josino, Maria Aparecida Alexandre, Valente Sá, Lívia Gurgel do Amaral, Silva, Antônio Adailson de Sousa, Barreto, Francisco Stefânio, Ferreira, José Roberto de Oliveira, Magalhães, Hemerson Iury Ferreira, Pinto Vieira, Ícaro Gusmão, Brito, Débora Hellen Almeida, Ricardo, Nágila Maria Pontes Silva, Barroso, Fátima Daiana Dias, da Costa, Érica Rayanne Mota, Júnior, Hélio Vitoriano Nobre, de Moraes, Manoel Odorico
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Journal of Health & Biological Sciences
• Texto Completo: https://periodicos.unichristus.edu.br/jhbs/article/view/4461
• topic: Saúde; Fluoxetine; Galactomannan; Mutagenicity; Chromosomal aberrations; Salmonella typhimurium /microsome assay

Objectives: The purpose of this study was to evaluate the mutagenic potential of fluoxetine and fluoxetine-galactomannan. Methods: Chromosomal aberration test and Salmonella typhimurium/microsome mutagenicity assay. Results: The results showed that fluoxetine (250 μg/mL) can cause chromosomal breaks of treated leukocytes and increase the frequency of reversion of the tester strains of S. typhimurium / microsome assay only at the highest concentration (5 mg/mL), while fluoxetine encapsulated in galactomannan did not cause these changes (leukocytes and S. typhimuriums strains). Conclusion: In summary, fluoxetine showed a mutagenic effect detectable only at high concentrations in both eukaryotic and prokaryotic models. Furthermore, the fluoxetine/galactomannan complex, in this first moment, prevented the mutagenicity attributed to fluoxetine, emphasizing that the present encapsulation process can be an alternative in preventing these effects in vitro.